Company intelligence / Profile preview

BrainVectis

Fontenay‑aux‑Roses, Île-de-France, Franceaskbio.com ↗

Ownership: Private
Development stage: Other

Overview

BrainVectis develops gene therapies targeting brain cholesterol metabolism by boosting CYP46A1 levels, aiming to treat neurodegenerative diseases such as Huntington's and Alzheimer's. No published late-stage clinical results as of now.

Therapeutic areas: Neurology
Modalities: Gene therapy
Industry: Biotech

Partnerships

Asklepios BioPharmaceutical ("AskBio")

Beyond the preview

Go deeper on BrainVectis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrainVectis.

Explore the full profile